Pregled bibliografske jedinice broj: 457645
The metabolic syndrome : an ongoing story
The metabolic syndrome : an ongoing story // Journal of physiology and pharmacology, 60 (2009), S7; 19-24 (međunarodna recenzija, pregledni rad, znanstveni)
CROSBI ID: 457645 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The metabolic syndrome : an ongoing story
Autori
Duvnjak, Lea ; Duvnjak, Marko
Izvornik
Journal of physiology and pharmacology (0867-5910) 60
(2009), S7;
19-24
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni
Ključne riječi
metabolic syndrome; insulin resistance; metabolic snydrome; insulin resistance; visceral obesity; type 2 diabetes; cardiovascular disease
(metabolic syndrome; insulin resistance; metabolic syndrome; insulin resistance; visceral obesity; type 2 diabetes; cardiovascular disease)
Sažetak
The metabolic syndrome refers to the clustering of cardiovascular risk factors that include diabetes, obesity, dyslipidaemia and hypertension. Due to various definitions and unexplained pathophysiology it is still a source of medical controversy. Insulin resistance and visceral obesity have been recognized as the most important pathogenic factors. Insulin resistance could be defined as the inability of insulin to produce its numerous actions, in spite of the unimpaired secretion from the beta cells. Metabolic abnormalities result from the interaction between the effects of insulin resistance located primarily in the muscle and adipose tissue and the adverse impact of the compensatory hyperinsulinaemia on tissues that remain normally insulin-sensitive. The clinical heterogeneity of the syndrome can be explained by its significant impact on glucose, fat and protein metabolism, cellular growth and differentiation, and endothelial function. Visceral fat represents a metabolically active organ, strongly related to insulin sensitivity. Moderating the secretion of adipocytokines like leptin, adiponectin, plasminogen activator inhibitor 1 (PAI-1), tumor necrosis factor alfa (TNF-alfa), interleukin-6 (IL-6) and resistin, it is associated with the processes of inflammation, endothelial dysfunction, hypertension and atherogenesis. In 2005, the International Diabetes Federation (IDF) has proposed a new definition, based on clinical criteria and designed for global application in clinical practice. Visceral obesity measured by waist circumference is an essential requirement for diagnosis ; other variables include increased triglyceride and decreased HDL levels, hypertension and glucose impairment. Whatever the uncertainties of definition and etiology, metabolic syndrome represents a useful and simple clinical concept which allows earlier detection of type 2 diabetes and cardiovascular disease.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Napomena
Rad je prezentiran na skupu 7th International Symposium on Cell/Tissue Injury and Cytoprotection/Organo-protection : Focus on GI Tract, održanom od 09.-11.09.2012., Hawaii.
POVEZANOST RADA
Projekti:
045-1080230-0516 - Metabolički sindrom u šećernoj bolesti tipa 1 (Smirčić-Duvnjak, Lea, MZOS ) ( CroRIS)
Ustanove:
Klinika za dijabetes, endokrinologiju i bolesti metabolizma Vuk Vrhovac,
KBC "Sestre Milosrdnice"
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- MEDLINE